Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 14;67(12):e0082923.
doi: 10.1128/aac.00829-23. Epub 2023 Nov 14.

Isavuconazole use and TDM in real-world pediatric practice

Berta Fernández Ledesma  1 , Natalia Mendoza-Palomar  1 , Susana Melendo Pérez  1 , Aurora Fernández-Polo  2 , Berta Renedo Miró  2 , Alba Pau Parra  2 , Sonia Luque Pardos  3 , Santiago Grau Cerrato  3 , Jaume Vima Bofarull  4 , María Teresa Martín-Gómez  5 , Montserrat Pujol Jover  6 , Maria Isabel Benítez-Carbante  7 , Cristina Díaz de Heredia  7 , Pere Soler-Palacin  8
Affiliations

Isavuconazole use and TDM in real-world pediatric practice

Berta Fernández Ledesma et al. Antimicrob Agents Chemother. .

Abstract

Isavuconazole (ISA) is approved for treating invasive aspergillosis and mucormycosis in adults, but its use in children remains off-label. We report on the use of ISA in real-world pediatric practice with 15 patients receiving ISA for treatment of invasive fungal infections. Therapeutic drug monitoring (TDM) was performed in all patients, with 52/111 (46.8%) Ctrough determinations out of range, thus supporting the need for TDM in children, especially those receiving extracorporeal membrane oxygenation (ECMO).

Keywords: ECMO; children; invasive fungal infection; isavuconazole; targeted drug monitoring.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Al-Rezqi A, Hawkes M, Doyle J, Richardson SE, Allen U. 2009. Invasive mold infections in iatrogenically immunocompromised children: an eight-yr review. Pediatr Transplant 13:545–552. doi: 10.1111/j.1399-3046.2008.01056.x - DOI - PubMed
    1. Burgos A, Zaoutis TE, Dvorak CC, Hoffman JA, Knapp KM, Nania JJ, Prasad P, Steinbach WJ. 2008. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics 121:e1286–e1294. doi: 10.1542/peds.2007-2117 - DOI - PubMed
    1. Dornbusch HJ, Manzoni P, Roilides E, Walsh TJ, Groll AH. 2009. Invasive fungal infections in children. Pediatr Infect Dis J 28:734–737. doi: 10.1097/INF.0b013e3181b076b1 - DOI - PubMed
    1. Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, Bow EJ, Rahav G, Neofytos D, Aoun M, Baddley JW, Giladi M, Heinz WJ, Herbrecht R, Hope W, Karthaus M, Lee D-G, Lortholary O, Morrison VA, Oren I, Selleslag D, Shoham S, Thompson GR, Lee M, Maher RM, Schmitt-Hoffmann A-H, Zeiher B, Ullmann AJ. 2016. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. The Lancet 387:760–769. doi: 10.1016/S0140-6736(15)01159-9 - DOI - PubMed
    1. Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR, Alangaden GJ, Brown JM, Fredricks DN, Heinz WJ, Herbrecht R, Klimko N, Klyasova G, Maertens JA, Melinkeri SR, Oren I, Pappas PG, Ráčil Z, Rahav G, Santos R, Schwartz S, Vehreschild JJ, Young J-A, Chetchotisakd P, Jaruratanasirikul S, Kanj SS, Engelhardt M, Kaufhold A, Ito M, Lee M, Sasse C, Maher RM, Zeiher B, Vehreschild M, VITAL and FungiScope Mucormycosis Investigators . 2016. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis 16:828–837. doi: 10.1016/S1473-3099(16)00071-2 - DOI - PubMed